[go: up one dir, main page]

MX9605741A - Clorhidrato cristalino del (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzisotiazol-2-il)-butil ]-aminometil} cromano. - Google Patents

Clorhidrato cristalino del (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzisotiazol-2-il)-butil ]-aminometil} cromano.

Info

Publication number
MX9605741A
MX9605741A MX9605741A MX9605741A MX9605741A MX 9605741 A MX9605741 A MX 9605741A MX 9605741 A MX9605741 A MX 9605741A MX 9605741 A MX9605741 A MX 9605741A MX 9605741 A MX9605741 A MX 9605741A
Authority
MX
Mexico
Prior art keywords
chlorhydrate
cromane
benzisotiazole
buty
aminomethyl
Prior art date
Application number
MX9605741A
Other languages
English (en)
Inventor
Alfons Grunenberg
Oliver Brehm
Michael Conrad
Dietrich Seidel
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX9605741A publication Critical patent/MX9605741A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La invencion se refiere a la forma cristalina del clorhidrato del compuesto (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihidro-ben zisotiazol-2-il)-butil]-aminometil}-cromamo, que es estable a temperatura ambiente. La modificacion cristalina V del clorhidrato es apropiada especialmente para la preparacion de medicamentos solidos, especialmente de medicamentos para el tratamiento de las degeneraciones neuronales.
MX9605741A 1995-11-22 1996-11-21 Clorhidrato cristalino del (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzisotiazol-2-il)-butil ]-aminometil} cromano. MX9605741A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19543478A DE19543478A1 (de) 1995-11-22 1995-11-22 Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman

Publications (1)

Publication Number Publication Date
MX9605741A true MX9605741A (es) 1997-05-31

Family

ID=7778081

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9605741A MX9605741A (es) 1995-11-22 1996-11-21 Clorhidrato cristalino del (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzisotiazol-2-il)-butil ]-aminometil} cromano.

Country Status (32)

Country Link
US (1) US5830908A (es)
EP (1) EP0775704B1 (es)
JP (1) JPH09143180A (es)
KR (1) KR970027079A (es)
CN (1) CN1086703C (es)
AR (1) AR004961A1 (es)
AT (1) ATE201872T1 (es)
AU (1) AU712922B2 (es)
BR (1) BR9605646A (es)
CA (1) CA2190700A1 (es)
CZ (1) CZ289730B6 (es)
DE (2) DE19543478A1 (es)
DK (1) DK0775704T3 (es)
EE (1) EE9600183A (es)
ES (1) ES2159342T3 (es)
GR (1) GR3036505T3 (es)
HU (1) HUP9603237A3 (es)
IL (1) IL119647A (es)
MX (1) MX9605741A (es)
MY (1) MY132473A (es)
NO (1) NO307340B1 (es)
NZ (1) NZ299780A (es)
PL (1) PL317090A1 (es)
PT (1) PT775704E (es)
RU (1) RU2181723C2 (es)
SG (1) SG44989A1 (es)
SI (1) SI0775704T1 (es)
SK (1) SK150096A3 (es)
TR (1) TR199600930A2 (es)
TW (1) TW449595B (es)
UA (1) UA45338C2 (es)
ZA (1) ZA969753B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ600126A (en) * 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
WO2010018217A2 (en) * 2008-08-15 2010-02-18 Boehringer Ingelheim International Gmbh Organic compounds for wound healing
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20120107080A (ko) 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
KR20220025926A (ko) 2010-06-24 2022-03-03 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
MX390363B (es) 2016-06-10 2025-03-20 Boehringer Ingelheim Int Combinacion de linagliptina y metformina

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748182A (en) * 1986-03-05 1988-05-31 Merrell Dow Pharmaceuticals Inc. Aromatic 2-aminoalkyl-1,2-benzoisothiazol-3(2H)one-1,1-dioxide derivatives and their use as anti-hypertensive and anxiolytic agents
US5300523A (en) * 1988-07-28 1994-04-05 Bayer Aktiengesellschaft Substituted aminomethyltetralins and their heterocyclic analogues
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE4138756A1 (de) * 1991-11-26 1993-05-27 Troponwerke Gmbh & Co Kg Kombination mit neuroprotektiver wirkung

Also Published As

Publication number Publication date
TW449595B (en) 2001-08-11
ATE201872T1 (de) 2001-06-15
ES2159342T3 (es) 2001-10-01
CA2190700A1 (en) 1997-05-23
MY132473A (en) 2007-10-31
EE9600183A (et) 1997-06-16
AU712922B2 (en) 1999-11-18
PT775704E (pt) 2001-09-28
AU7177296A (en) 1997-05-29
RU2181723C2 (ru) 2002-04-27
HU9603237D0 (en) 1997-01-28
CZ342896A3 (en) 1997-06-11
EP0775704A1 (de) 1997-05-28
NZ299780A (en) 1998-09-24
KR970027079A (ko) 1997-06-24
UA45338C2 (uk) 2002-04-15
ZA969753B (en) 1997-03-25
BR9605646A (pt) 1998-08-18
EP0775704B1 (de) 2001-06-06
CN1086703C (zh) 2002-06-26
DK0775704T3 (da) 2001-07-23
HUP9603237A2 (hu) 1998-01-28
DE59607040D1 (de) 2001-07-12
NO964950L (no) 1997-05-23
IL119647A0 (en) 1997-02-18
TR199600930A2 (tr) 1997-06-21
NO964950D0 (no) 1996-11-21
IL119647A (en) 1999-12-22
NO307340B1 (no) 2000-03-20
SG44989A1 (en) 1997-12-19
CZ289730B6 (cs) 2002-03-13
GR3036505T3 (en) 2001-11-30
DE19543478A1 (de) 1997-05-28
US5830908A (en) 1998-11-03
HUP9603237A3 (en) 1998-12-28
JPH09143180A (ja) 1997-06-03
SI0775704T1 (en) 2001-08-31
AR004961A1 (es) 1999-04-07
PL317090A1 (en) 1997-05-26
SK150096A3 (en) 1997-08-06
CN1152574A (zh) 1997-06-25

Similar Documents

Publication Publication Date Title
MX9605741A (es) Clorhidrato cristalino del (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzisotiazol-2-il)-butil ]-aminometil} cromano.
MY113733A (en) Salts of an anti-migraine indole derivative
ZA968956B (en) Substituted 2,4-imidazolidinedione compounds as pharmaceutical active ingredients
TR200101961T2 (tr) 1,2-halkalı kinolin türevleri
HUP0101372A3 (en) Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
BG103947A (en) Derivatives of 9-oxymerythromycin
BR0109703A (pt) Derivados de piperazina
IL140093A0 (en) Glycopeptide derivatives and pharmaceutical compositions containing the same
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
DE69229339D1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
AU1945495A (en) Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
BG103260A (en) The application of 1-hydroxy-2-pyridons for the treatment of seborrheic dermatitis
ATE125541T1 (de) Reine kristalline form von rifapentin.
NZ332545A (es)
EP1008345A4 (en) ANTI-ALLERGIC AGENTS
NO973341L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for vasodilatorisk behandling eller profylakse
MY138319A (en) 1,5-benzodiazepine derivatives
ES2184285T3 (es) Compuestos farmaceuticos que contienen diclorhidrato de cinconina.
AU5768298A (en) Use of benzoylalkyl-1,2,3,6-tetrahydropyridins
IL116557A0 (en) Antiherpes peptidomimetic compounds their preparation and pharmaceutical compositions containing them
BR9915898A (pt) Compostos, composição farmacêutica, e, utilização de um composto
TWI231815B (en) Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents